Transgender Hormonal Treatment

Rebecca Webb; Joshua D. Safer

doi:10.1016/B978-0-323-47912-7.00028-7

Transgender Hormonal Treatment

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Transgender individuals have biological gender identities that differ from the sex recorded at birth. To proceed with medical therapy, a diagnosis of gender incongruence must be made. Although not all transgender patients desire medical intervention, hormone treatment and surgeries are available. Hormone therapy is safe, and appropriate screening for malignancy and adverse events should be considered. For adolescents, initial treatment includes puberty blockade before hormone therapy and surgery. These treatments can be destructive of fertility, thus preservation should always be discussed. Barriers to effective care for transgender patients exist, necessitating an increase in the number of knowledgeable transgender health care providers.

Original language	English
Title of host publication	Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth Edition
Publisher	Elsevier Inc.
Pages	709-716.e1
ISBN (Electronic)	9780323582322
ISBN (Print)	9780323479127
DOIs	https://doi.org/10.1016/B978-0-323-47912-7.00028-7
State	Published - 2019
Externally published	Yes

Keywords

Barriers to care
Children and adolescents
Fertility preservation
Gender identity
Gender incongruence
Hormonal therapy for transgender men and women
Lack of transgender medical education
Risk concerns and screening for malignancy
Surgeries for transgender men and women
Transgender

Access to Document

10.1016/B978-0-323-47912-7.00028-7

Cite this

@inbook{b3af36cd20f7413ebd0186830e141725,

title = "Transgender Hormonal Treatment",

abstract = "Transgender individuals have biological gender identities that differ from the sex recorded at birth. To proceed with medical therapy, a diagnosis of gender incongruence must be made. Although not all transgender patients desire medical intervention, hormone treatment and surgeries are available. Hormone therapy is safe, and appropriate screening for malignancy and adverse events should be considered. For adolescents, initial treatment includes puberty blockade before hormone therapy and surgery. These treatments can be destructive of fertility, thus preservation should always be discussed. Barriers to effective care for transgender patients exist, necessitating an increase in the number of knowledgeable transgender health care providers.",

keywords = "Barriers to care, Children and adolescents, Fertility preservation, Gender identity, Gender incongruence, Hormonal therapy for transgender men and women, Lack of transgender medical education, Risk concerns and screening for malignancy, Surgeries for transgender men and women, Transgender",

author = "Rebecca Webb and Safer, {Joshua D.}",

year = "2019",

doi = "10.1016/B978-0-323-47912-7.00028-7",

language = "English",

isbn = "9780323479127",

pages = "709--716.e1",

booktitle = "Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth Edition",

publisher = "Elsevier Inc.",

address = "United States",

}

TY - CHAP

T1 - Transgender Hormonal Treatment

AU - Webb, Rebecca

AU - Safer, Joshua D.

PY - 2019

Y1 - 2019

N2 - Transgender individuals have biological gender identities that differ from the sex recorded at birth. To proceed with medical therapy, a diagnosis of gender incongruence must be made. Although not all transgender patients desire medical intervention, hormone treatment and surgeries are available. Hormone therapy is safe, and appropriate screening for malignancy and adverse events should be considered. For adolescents, initial treatment includes puberty blockade before hormone therapy and surgery. These treatments can be destructive of fertility, thus preservation should always be discussed. Barriers to effective care for transgender patients exist, necessitating an increase in the number of knowledgeable transgender health care providers.

AB - Transgender individuals have biological gender identities that differ from the sex recorded at birth. To proceed with medical therapy, a diagnosis of gender incongruence must be made. Although not all transgender patients desire medical intervention, hormone treatment and surgeries are available. Hormone therapy is safe, and appropriate screening for malignancy and adverse events should be considered. For adolescents, initial treatment includes puberty blockade before hormone therapy and surgery. These treatments can be destructive of fertility, thus preservation should always be discussed. Barriers to effective care for transgender patients exist, necessitating an increase in the number of knowledgeable transgender health care providers.

KW - Barriers to care

KW - Children and adolescents

KW - Fertility preservation

KW - Gender identity

KW - Gender incongruence

KW - Hormonal therapy for transgender men and women

KW - Lack of transgender medical education

KW - Risk concerns and screening for malignancy

KW - Surgeries for transgender men and women

KW - Transgender

UR - http://www.scopus.com/inward/record.url?scp=85046605556&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-47912-7.00028-7

DO - 10.1016/B978-0-323-47912-7.00028-7

M3 - Chapter

AN - SCOPUS:85046605556

SN - 9780323479127

SP - 709-716.e1

BT - Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth Edition

PB - Elsevier Inc.

ER -

Transgender Hormonal Treatment

Abstract

Keywords

Access to Document

Fingerprint

Cite this